Literature DB >> 20698802

Ability among adolescents for the metabolic syndrome to predict elevations in factors associated with type 2 diabetes and cardiovascular disease: data from the national health and nutrition examination survey 1999-2006.

Mark D DeBoer1, Matthew J Gurka.   

Abstract

OBJECTIVE: The aim of this study was to compare currently proposed sets of pediatric metabolic syndrome criteria for the ability to predict elevations in "surrogate" factors that are associated with metabolic syndrome and with future cardiovascular disease and type 2 diabetes mellitus. These surrogate factors were fasting insulin, hemoglobin A1c (HbA1c), high-sensitivity C-reactive protein (hsCRP), and uric acid.
METHODS: Waist circumference (WC), blood pressure, triglycerides, high-density lipoprotein cholesterol (HDL-C), fasting glucose, fasting insulin, HbA1c, hsCRP, and uric acid measurements were obtained from 2,624 adolescent (12-18 years old) participants of the 1999-2006 National Health and Nutrition Examination Surveys. We identified children with metabolic syndrome as defined by six commonly used sets of pediatric metabolic syndrome criteria. We then defined elevations in the surrogate factors as values in the top 5% for the cohort and calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for each set of metabolic syndrome criteria and for each surrogate factor.
RESULTS: Current pediatric metabolic syndrome criteria exhibited variable sensitivity and specificity for surrogate predictions. Metabolic syndrome criteria had the highest sensitivity for predicting fasting insulin (40-70%), followed by uric acid (31-54%), hsCRP (13-31%), and HbA1c (7-21%). The criteria of de Ferranti (which includes children with WC >75(th) percentile, compared to all other sets including children with WC >90(th) percentile) exhibited the highest sensitivity for predicting each of the surrogates, with only modest decrease in specificity compared to the other sets of criteria. However, the de Ferranti criteria also exhibited the lowest PPV values. Conversely, the pediatric International Diabetes Federation criteria exhibited the lowest sensitivity and the highest specificity.
CONCLUSIONS: Pediatric metabolic syndrome criteria exhibit moderate sensitivity for detecting elevations in surrogate factors associated with metabolic syndrome and with risk for future disease. Inclusion of children with more modestly elevated WC improved sensitivity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20698802      PMCID: PMC3046372          DOI: 10.1089/met.2010.0008

Source DB:  PubMed          Journal:  Metab Syndr Relat Disord        ISSN: 1540-4196            Impact factor:   1.894


  67 in total

1.  Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study.

Authors:  Elizabeth Selvin; Josef Coresh; Sherita H Golden; Frederick L Brancati; Aaron R Folsom; Michael W Steffes
Journal:  Arch Intern Med       Date:  2005-09-12

2.  Serum uric acid is significantly related to the components of the metabolic syndrome in Japanese workingmen.

Authors:  Tomoyuki Kawada; Toshiaki Otsuka; Masao Katsumata; Hiroko Suzuki
Journal:  J Cardiometab Syndr       Date:  2007

3.  Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus.

Authors:  S Goya Wannamethee; A Gerald Shaper; Lucy Lennon; Richard W Morris
Journal:  Arch Intern Med       Date:  2005 Dec 12-26

4.  Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.

Authors:  Marilda Mazzali; John Kanellis; Lin Han; Lili Feng; Yi-Yang Xia; Qiang Chen; Duk-Hee Kang; Katherine L Gordon; Susumu Watanabe; Takahiko Nakagawa; Hui Y Lan; Richard J Johnson
Journal:  Am J Physiol Renal Physiol       Date:  2002-06

5.  Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study.

Authors:  Arnold B Alper; Wei Chen; Lillian Yau; Sathanur R Srinivasan; Gerald S Berenson; L Lee Hamm
Journal:  Hypertension       Date:  2004-11-29       Impact factor: 10.190

6.  C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999-2000.

Authors:  Earl S Ford; Wayne H Giles; Gary L Myers; Nader Rifai; Paul M Ridker; David M Mannino
Journal:  Clin Chem       Date:  2003-08       Impact factor: 8.327

Review 7.  Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.

Authors:  Adilson Guilherme; Joseph V Virbasius; Vishwajeet Puri; Michael P Czech
Journal:  Nat Rev Mol Cell Biol       Date:  2008-05       Impact factor: 94.444

8.  Childhood predictors of the metabolic syndrome in middle-aged adults: the Muscatine study.

Authors:  Trudy L Burns; Elena M Letuchy; Richard Paulos; John Witt
Journal:  J Pediatr       Date:  2009-09       Impact factor: 4.406

9.  Determinants of early atherosclerosis in obese children and adolescents.

Authors:  Véronique Beauloye; Francis Zech; Hiep Thi Mong Tran; Philippe Clapuyt; Marc Maes; Sonia M Brichard
Journal:  J Clin Endocrinol Metab       Date:  2007-05-22       Impact factor: 5.958

10.  Association between serum uric acid and development of type 2 diabetes.

Authors:  Satoru Kodama; Kazumi Saito; Yoko Yachi; Mihoko Asumi; Ayumi Sugawara; Kumiko Totsuka; Aki Saito; Hirohito Sone
Journal:  Diabetes Care       Date:  2009-06-23       Impact factor: 19.112

View more
  23 in total

1.  Geographical variation in the prevalence of obesity and metabolic syndrome among US adolescents.

Authors:  M D DeBoer; S L Filipp; M J Gurka
Journal:  Pediatr Obes       Date:  2018-12-04       Impact factor: 4.000

2.  Racial/ethnic and sex differences in the relationship between uric acid and metabolic syndrome in adolescents: an analysis of National Health and Nutrition Survey 1999-2006.

Authors:  Mark D DeBoer; Lili Dong; Matthew J Gurka
Journal:  Metabolism       Date:  2011-10-13       Impact factor: 8.694

Review 3.  Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: a need for screening tools to target interventions.

Authors:  Mark D DeBoer
Journal:  Nutrition       Date:  2012-09-28       Impact factor: 4.008

4.  Ethnicity, obesity and the metabolic syndrome: implications on assessing risk and targeting intervention.

Authors:  Mark D Deboer
Journal:  Expert Rev Endocrinol Metab       Date:  2011-03

5.  Correlation of metabolic syndrome severity with cardiovascular health markers in adolescents.

Authors:  Arthur M Lee; Matthew J Gurka; Mark D DeBoer
Journal:  Metabolism       Date:  2017-01-13       Impact factor: 8.694

6.  A metabolic syndrome severity score to estimate risk in adolescents and adults: current evidence and future potential.

Authors:  Arthur M Lee; Matthew J Gurka; Mark D DeBoer
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-02-12

7.  Serum Alanine Aminotransferase Trends and Their Relationship with Obesity and Metabolic Syndrome in United States Adolescents, 1999-2014.

Authors:  Cyrelle R Fermin; Arthur M Lee; Stephanie L Filipp; Matthew J Gurka; Mark D DeBoer
Journal:  Metab Syndr Relat Disord       Date:  2017-05-18       Impact factor: 1.894

8.  Distribution and correlates of the metabolic syndrome in adults living in the San Juan Metropolitan Area of Puerto Rico.

Authors:  Cynthia M Pérez; Ana P Ortiz; Manuel Guzmán; Erick Suárez
Journal:  P R Health Sci J       Date:  2012-09       Impact factor: 0.705

9.  Severity of the metabolic syndrome as a predictor of type 2 diabetes between childhood and adulthood: the Princeton Lipid Research Cohort Study.

Authors:  Mark D DeBoer; Matthew J Gurka; Jessica G Woo; John A Morrison
Journal:  Diabetologia       Date:  2015-09-17       Impact factor: 10.122

10.  Obesity, metabolic syndrome, and insulin resistance in urban high school students of minority race/ethnicity.

Authors:  Michael Turchiano; Victoria Sweat; Arthur Fierman; Antonio Convit
Journal:  Arch Pediatr Adolesc Med       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.